$NCLR to perform clinical study on effects of ketamine KetamineOne Capital, trading under $MEDI on the NEO, has partnered with Cognetivity Neurosciences to perform a collaborative clinical study on the effects of ketamine therapy for depression and PTSD.
The study should add an extensive body of data to validate Cognetivity’s Integrated Cognitive Assessment tool that is currently deployed throughout $MEDI’s network of clinics.
As the therapeutic psychedelics industry is still in its infancy, I view companies progressing the industry's validity like $MEDI to be an integral component of bringing this industry to the mainstream.
With the psychedelic industry expected to reach a value of $10.75 billion by 2027, shares of $MEDI are looking like a good bargain at the current price of $.45 after seeing a 78% decline.
Psychedelics are definitely a long play currently, but the industry as a whole seems to be trading at a large discount given the outlook.
$MEDI is currently trading at $.45 and the company is valued at an MCP of $54.07 million.
https://ceo.ca/@nasdaq/ketamine-one-partners-with-cognetivity-neurosciences